Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT03795311	TitleEvaluación de la eficacia y la seguridad del tratamiento con FOLFIRINOX3 Bevacizumab en pacientes con cáncer colorrectal (FOLFIRINOX 3)	Fase Phase 1, Phase 2	Date Added 2019-01-07	Ubicación Francia	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas FOLFIRINOX Bevacizumab	Etiquetas MSS/ MMRp
NCT ID NCT03785249	TitleEstudio de fase 1/2 de MRTX849 en pacientes con cáncer que presentan una mutación KRAS G12C KRYSTAL-1	Fase Fase 1	Date Added 2018-12-24	Ubicación Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas afatinib, cetuximab, MRTX849, Pembrolizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03783403	TitleA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers	Fase Fase 1	Date Added 2018-12-21	Ubicación Alabama, United States Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canadá Francia Italia Corea, República de España Reino Unido	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas CC-95251, cetuximab, Rituximab	Etiquetas MSS/ MMRp
NCT ID NCT03772561	TitlePhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies	Fase Fase 1	Date Added 2018-12-11	Ubicación Singapur	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas AZD5363+Olaparib+Durvalumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03745326	TitleAdministración de linfocitos de sangre periférica transducidos con un receptor murino de células T que reconoce la variante G12D del RAS mutado en pacientes HLA-A*11:01	Fase Phase 1, Phase 2	Date Added 2018-11-19	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03740256	TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors	Fase Fase 1	Date Added 2018-11-14	Ubicación Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas CAdVEC	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03727763	TitleCetuximab y vemurafenib más FOLFIRI para el cáncer colorrectal avanzado con mutación BRAF V600E (IMPROVEMENT)	Fase Fase 2	Date Added 2018-11-01	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas cetuximab, Vemurafenib	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03711058	TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer	Fase Phase 1, Phase 2	Date Added 2018-10-18	Ubicación Maryland, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Copanlisib, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT03692429	TitlealloSHRINK - Régimen estándar de quimioterapia e inmunoterapia con células T receptoras de antígenos quiméricos CYAD-101 alogénicas basadas en NKG2D.	Fase Fase 1	Date Added 2018-10-02	Ubicación Florida, United States Bélgica	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas CYAD-101, FOLFIRI, FOLFOX	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03673787	TitleUn ensayo de ipatasertib en combinación con atezolizumab	Fase Fase 1	Date Added 2018-09-17	Ubicación Reino Unido	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Atezolizumab, Ipatasertib	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 211 to 220 of 299 entries